[{"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":12739000.0,"ShareBasedCompensation_1_Q1_USD":2381000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q1_USD":94000.0,"IncreaseDecreaseInOtherOperatingLiabilities_1_Q1_USD":24000.0,"IncreaseDecreaseInPrepaidExpense_1_Q1_USD":-1283000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1_Q1_USD":24.38,"Goodwill_0_Q1_USD":17260000.0,"OtherAssetsNoncurrent_0_Q1_USD":5962000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1_Q1_shares":518325.0,"StockIssuedDuringPeriodValueNewIssues_1_Q1_USD":42999000.0,"IncreaseDecreaseInAccruedLiabilities_1_Q1_USD":-6987000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-25201000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q1_USD":6287000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":16130000.0,"DepreciationDepletionAndAmortization_1_Q1_USD":39000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":150515000.0,"InterestIncomeExpenseNet_1_Q1_USD":-1938000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q1_USD":6287000.0,"OtherLiabilitiesCurrent_0_Q1_USD":798000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":2381000.0,"AccountsPayableTradeCurrent_0_Q1_USD":6788000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":4121000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q1_USD":-6544000.0,"AccretionExpense_1_Q1_USD":2040000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":18672000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1_Q1_USD":-625000.0,"IncreaseDecreaseInOtherNoncurrentAssets_1_Q1_USD":-135000.0,"ProceedsFromStockOptionsExercised_1_Q1_USD":94000.0,"OperatingIncomeLoss_1_Q1_USD":-29550000.0,"OperatingExpenses_1_Q1_USD":31099000.0,"CommonStockSharesAuthorized_0_Q1_shares":30000000.0,"AdditionalPaidInCapital_0_Q1_USD":291221000.0,"Assets_0_Q1_USD":182109000.0,"AssetsCurrent_0_Q1_USD":158333000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":150515000.0,"CommonStockSharesIssued_0_Q1_shares":14977855.0,"CommonStockSharesOutstanding_0_Q1_shares":14977855.0,"CommonStockValue_0_Q1_USD":149000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-2.23,"GeneralAndAdministrativeExpense_1_Q1_USD":8153000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":0.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":2233000.0,"Liabilities_0_Q1_USD":68675000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":182109000.0,"LiabilitiesCurrent_0_Q1_USD":15147000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":43093000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-23796000.0,"NetIncomeLoss_1_Q1_USD":-31488000.0,"OtherOperatingIncomeExpenseNet_1_Q1_USD":-6816000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":7818000.0,"ProceedsFromIssuanceOfCommonStock_1_Q1_USD":42999000.0,"ProfitLoss_1_Q1_USD":-31488000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":554000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-190675000.0,"StockholdersEquity_0_Q1_USD":113434000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":14132217.0,"AccruedLiabilitiesCurrent_0_Q1_USD":7561000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.01,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":1549000.0,"StockIssuedDuringPeriodValueShareBasedCompensationGross_1_Q1_USD":2381000.0,"Ticker":"ALBO","CIK":"1322505","name":"ALBIREO PHARMA, INC.","OfficialName":"Albireo Pharma Inc. Common Stock","form":"10-Q","period":"20200331","fy":"2020.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"688702712.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200507"}]